Halozyme Therapeutics (NASDAQ:HALO) Director Matthew Posard Sells 5,000 Shares of Company Stock

Halozyme Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Halozyme director Matthew Posard sold 5,000 shares for $482,150 at an average price of $96.43 under a pre-arranged Rule 10b5-1 plan. He retained 48,609 shares after the sale, a 9.33% reduction in his position.
  • Halozyme’s latest quarter beat analyst expectations: EPS was $2.39 versus $2.30 expected, while revenue rose 39.1% year over year to $492.97 million.
  • Analysts’ consensus rating is Hold, with an average price target of $108.18. Institutional investors own 97.79% of the company’s shares.
  • Interested in Halozyme Therapeutics? Here are five stocks we like better.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Matthew Posard sold 5,000 shares of the firm's stock in a transaction dated Wednesday, November 18th. The stock was sold at an average price of $96.43, for a total value of $482,150.00. Following the completion of the transaction, the director owned 48,609 shares of the company's stock, valued at approximately $4,687,365.87. This represents a 9.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Halozyme Therapeutics Price Performance

HALO stock traded down $0.17 during mid-day trading on Wednesday, reaching $95.80. 1,609,327 shares of the company traded hands, compared to its average volume of 1,981,696. The company has a fifty day moving average price of $114.04 and a 200-day moving average price of $85.75. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $134.00. The company has a market capitalization of $10.92 billion, a P/E ratio of 24.38, a P/E/G ratio of 0.36 and a beta of 0.92. The company has a debt-to-equity ratio of 13.50, a current ratio of 3.88 and a quick ratio of 3.60.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.30 by $0.09. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 751.81%. The firm had revenue of $492.97 million for the quarter, compared to the consensus estimate of $491.63 million. During the same period in the prior year, the firm posted $1.72 earnings per share. The company's revenue for the quarter was up 39.1% on a year-over-year basis. As a group, analysts anticipate that Halozyme Therapeutics, Inc. will post 8.34 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have commented on HALO. Wall Street Zen downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Saturday, November 7th. TD Cowen reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a report on Monday. Stifel Nicolaus set a $130.00 price target on shares of Halozyme Therapeutics in a report on Friday, October 16th. Weiss Ratings upgraded Halozyme Therapeutics from a "buy (b)" rating to a "buy (b+)" rating in a research report on Monday, November 9th. Finally, Benchmark reissued a "buy" rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $108.18.

Get Our Latest Research Report on HALO

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of HALO. Congress Asset Management Co. increased its position in shares of Halozyme Therapeutics by 85.6% during the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company's stock valued at $251,890,000 after buying an additional 1,052,509 shares during the period. Bank of America Corp DE bought a new position in Halozyme Therapeutics in the second quarter worth about $214,504,000. First Trust Advisors LP lifted its holdings in Halozyme Therapeutics by 28.3% in the third quarter. First Trust Advisors LP now owns 1,817,824 shares of the biopharmaceutical company's stock worth $200,688,000 after buying an additional 400,761 shares during the period. William Blair Investment Management LLC purchased a new stake in Halozyme Therapeutics in the second quarter worth about $196,540,000. Finally, Stephens Investment Management Group LLC lifted its holdings in Halozyme Therapeutics by 1.5% in the third quarter. Stephens Investment Management Group LLC now owns 1,413,040 shares of the biopharmaceutical company's stock worth $156,000,000 after buying an additional 20,221 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Company Profile

(Get Free Report)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Read More

Insider Buying and Selling by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Halozyme Therapeutics Right Now?

Before you consider Halozyme Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Halozyme Therapeutics wasn't on the list.

While Halozyme Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines